ArticleScientific reports2025
Characterization and evaluation of the fruit mucilage of Cordia africana as tablet binder in paracetamol tablet formulation: optimization study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have revealed that the fruit mucilage of different species of Cordia is found to be an excellent binder in tablet manufacturing. However, the binding ability of the mucilage of Cordia Africana (CM) is not yet established. Therefore, this study aimed to evaluate the tablet-binding ability of the CM using paracetamol as a model drug. The fruit of Cordia Africana was extracted with the maceration technique and characterized for different properties, such as its compatibility with the model drug (paracetamol) using the Fourier transform infrared spectroscopy (FTIR) and its crystallinity nature with X-ray Diffractometer (XRD). Granules were prepared using the wet granulation method and compressed into tablets. The prepared tablets were evaluated for their hardness, disintegration time, friability, and drug release profile. The effect of these independent variables was further studied and optimized using the central composite design (CCD). The yield of extracted CM powder was 29%. The FTIR study revealed that the CM is compatible with the model drug. The loss in drying and moisture sorption studies was 6 ± 0.02% and 1.3-6.7%, respectively. The granules exhibited good flowability (angle of repose < 30 °) and compressibility properties with Carr's and Hausner ratios of < 10 and < 1.11, respectively. All the prepared tablets have shown a hardness value of less than 100 N and a disintegration time in the range of 0.55 to 10.27 min. The ANOVA analysis for model adequacy testing confirmed the adequacy of the optimization model. Accordingly, the model provided an optimum formulation at 5.32% of CM concentration, 5% of disintegrant (Starch), and 76.71 N of compression force (CF). Under this condition, the software predicted 83.3% drug release at 30 min and 0.63 of friability. The validity of this optimum formulation was confirmed experimentally. The CM can be used as an alternative binder for tablets, and the optimization model was proven to be effective in identifying the optimum concentration of the CM along with CF and ST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.